Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2014

Every FDA drug recall initiated in 2014, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,309 recalls, newest first.

Class III · Low risk

Simvastatin Tablets

Failed Impurities/Degradation Specifications: Product failed a known impurity specification.

Terminated Impurity / degradation Micro Labs Usa, Inc S NDC 42571-080-90 D-0409-2015
Class III · Low risk

Simvastatin Tablets

Failed Impurities/Degradation Specifications: Product failed a known impurity specification.

Terminated Impurity / degradation Micro Labs Usa, Inc S NDC 42571-0040-90 D-0408-2015
Class III · Low risk

Simvastatin Tablets

Failed Impurities/Degradation Specifications: Product failed a known impurity specification.

Terminated Impurity / degradation Micro Labs Usa, Inc S NDC 42571-0020-10 D-0407-2015
Class III · Low risk

Eye Drops Advanced Relief

CGMP Deviations: Active Pharmaceutical Ingredient (API) used for manufacture was stored in a non-GMP compliant warehouse at S.I.M.S., Italy.

Terminated cGMP deviation K C Pharmaceuticals Inc D-0323-2015
Class III · Low risk

Eye Drops Industrial Strength

CGMP Deviations: Active Pharmaceutical Ingredient (API) used for manufacture was stored in a non-GMP compliant warehouse at S.I.M.S., Italy.

Terminated cGMP deviation K C Pharmaceuticals Inc D-0322-2015
Class III · Low risk

Eye Drops A.C.

CGMP Deviations: Active Pharmaceutical Ingredient (API) used for manufacture was stored in a non-GMP compliant warehouse at S.I.M.S., Italy.

Terminated cGMP deviation K C Pharmaceuticals Inc D-0321-2015
Class III · Low risk

Eye Drops (Tetrahydrozoline HCl 0.05%)

CGMP Deviations: Active Pharmaceutical Ingredient (API) used for manufacture was stored in a non-GMP compliant warehouse at S.I.M.S., Italy.

Terminated cGMP deviation K C Pharmaceuticals Inc D-0320-2015
Class I · High risk

MitoXANTRONE Injection

Failed Stability Specifications: Product is subpotent and has out of specification known and unknown impurities.

Terminated Stability / shelf life Hospira Inc. D-0433-2015
Class II · Moderate risk

Tikosyn (dofetilide)

Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.

Terminated Failed specification Pfizer Inc. NDC 0069-5800-61 D-0292-2015
Class II · Moderate risk

Benzonatate Capsules

Failed Tablet/Capsule Specifications: Recall due to wet and/or leaking capsules.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-248-01 D-0299-2015
Class III · Low risk

Dacarbazine

Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

Terminated Failed specification Hospira Inc. NDC 61703-327-22 D-0313-2015
Class II · Moderate risk

HydrALAZINE Hydrochloride Tablets

Presence of Foreign Substance: Par Pharmaceutical, Inc. is recalling one lot of HydrALAZINE Hydrochloride tablets due to the presence of small aluminum particles.

Terminated Particulate / foreign matter Par Pharmaceutical Inc. D-0332-2015
Class II · Moderate risk

Ginseng Kianpi Pil

Marketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared dexamethasone and cyproheptadine which are FDA approved drugs making this product an unapproved drug.

Terminated Chemical / undeclared One and Zen D-0329-2015
Class II · Moderate risk

Mercaptopurine Tablets

Failed USP Dissolution Test Requirements: This sub-recall is in response to Prometheus Laboratories Inc. recall for Mercaptopurine USP 50mg because the lot does not meet the specification for dissolution.

Terminated Dissolution failure American Health Packaging NDC 68084-325-21 D-0300-2015
Class II · Moderate risk

Zonisamide active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-960-2015
Class II · Moderate risk

Zolmitriptan active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-959-2015
Class II · Moderate risk

Zoledronic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-958-2015
Class II · Moderate risk

Zinc Pyrithione active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-957-2015
Class II · Moderate risk

Zidovudine active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-956-2015
Class II · Moderate risk

Voriconazole active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-955-2015
Class II · Moderate risk

Vincristine Sulfate active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-954-2015
Class II · Moderate risk

Vidarbine Monophosphate active pharmaceutical ingredient packaged…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-953-2015
Class II · Moderate risk

Venlafaxine HCl active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-952-2015

Recalls by year